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Abstract
How do we determine the mutational effects in exome sequencing data with
little or no statistical evidence? Can protein structural information fill in the
gap of not having enough statistical evidence? In this work, we answer the
two questions with the goal towards determining pathogenic effects of rare
variants in rare disease. We take the approach of determining the importance
of point mutation loci focusing on protein structure features. The proposed
structure-based features contain information about geometric, physicochemical,
and functional information of mutation loci and those of structural neighbors
of the loci. The performance of the structure-based features trained on 80%
of HumDiv and tested on 20% of HumDiv and on ClinVar datasets showed
high levels of discernibility in the mutation’s pathogenic or benign effects: F
score of 0.71 and 0.68 respectively using multi-layer perceptron. Combining
structure- and sequence-based feature further improve the accuracy: F score
of 0.86 (HumDiv) and 0.75 (ClinVar). Also, careful examination of the rare
variants in rare diseases cases showed that structure-based features are important
in discerning importance of variant loci.
Author summary
We explore how well features that do not rely on sample sizes can determine the
pathogenic effects of variant with the goals to correctly determine the pathogenic
effects of rare variants in rare disease. We examined the deterministic factor
of loci-based features in classifying pathogenic variant verses benign variant
focusing on the structure-based features as a way to be independent of the
number of samples available for a disease. Unlike the previous studies that tend
to ignore structure-based features, we emphasize the structure-based features
and enhance it by using information from multiple homolog structures and from
structural neighbors. As results, we can get up to F score of 0.86 using only the
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loci-based information and F score of 0.71 using only the loci-based structure-
based features. High F scores and empirical examination of rare variant in rare
diseases mapped to structures shows that where the variant have occurred in
structure is an important factor in determining pathogenic effects.
Introduction
Rare diseases have been known to affect over 350 million people worldwide having
over 7,000 different rare diseases 80% of which are due to genetic factors [15].
Compared to common and complex disease, rare disease are often heterogeneous,
rare (low minor allele frequency less than 1%), and are often hereditary [11,12]
Many rare diseases can be cared for if diagnosed early and optimally managed.
However, accurate diagnosis, adequate information, and ongoing targeted care
are significant challenges in rare disease treatment. Of many challenges, a quick
and non-statistical method for identifying causal variant of rare diseases through
mutation prioritization forms the basis for fast and accurate diagnosis as well as
for providing effective treatment suggestions [7, 34].
The goal of variant (mutation) prioritization is to determine the relative
importance of the variation in the context of disease mechanism. The informatics
approach for mutation prioritization considers two factors: the importance of the
variant loci and the severity of the mutation itself. The importance of the loci is
a prior knowledge that is independent of the variation given the loci. This means
the importance of the loci, i.e. loci weights, can be trained and learned in the
preprocessing step independent of disease types thus combined data from several
diseases can be used. On the other hand, the severity of the mutation rely on the
information of the mutation compared to wild-type and often requires statistical
measures for specific diseases of interest. Although both factors are important in
determining the effect of a variant, it will be difficult to determine to causality if
the severity of variant is measure based on statistical means of specific disease for
rare variant cases. Thus it is meaningful to study the how well prior information
alone can determine the pathogenic effect. Thus, we propose to approach this
challenge by separating out the features of determining the importance of loci
and for determining the severity of mutation itself and focusing on determination
of the importance of loci in terms of function.
Considering the source of information that characterizes loci in a genome
sequence, the features, generated from the two factors previously mentioned,
can be separated to sequence-based features and structure-based features. Most
sequence-based methods generate variant characteristics from protein and DNA
sequences via multiple sequence alignment to determine the effect variants [29,32].
Sequence-based features often include sequence conservation related scores such
as substitutions scores for protein coding regions. Divers type of features can
be extracted from protein structure and they can be classified largely to physio-
chemical properties, structure stability, and binding information. Physiochemical
properties include hydrophobicity, amino acid (AA) weight, AA volume, and
isoelectric point [19]. Structure stability properties include B-factor, secondary
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structure information, and region in Ramachandran plot [1, 9]. Binding site
information includes the interaction of mutation site with other biomolecules [31].
Sequence-based features, mostly due to their abundance and easiness of usage,
have been widely used in finding causal genes. The strength of sequence-
based methods is that it can be extended non-coding regions of the whole
genome [2,23,49]. On the other hand, structure features are limited to protein
coding regions, however, provides more direct information about the function. In
fact, exome sequencing, sequencing of the protein coding areas, has been found
to be effective means of detecting pathogenic genes as many alleles associated
with hereditary diseases, including many rare diseases, have been discovered to
alter protein coding nucleotides [5].
Features used for pathogenic single nucleotide variant (SNV) prediction
methods are generally sequence-based only or sequence and structure combined.
Although there have been several extensive studies for sequence-based features
due to their abundance and easiness of usage, there has not been a rigorously
extensive examination of structure-based features in the causal mutation predic-
tions. Many structure focused methods are limited in application as specific to
cancer [9], are more of an annotator [17]. Ones that are more general, considers
the structure-based features as minor features [1,2,33]. We believe this misunder-
standing of structure features being minor is due to the relatively limited number
and coverage of structural data compared to the sequence as well as relatively
careless processing of structural data which has more divergent information and
is not due to the importance of structural information. Our study here is show
that structure-based features are important in large study. The limitations such
as low coverage and limited function information can be address via various
computational prediction methods, such as structure prediction in presence of
mutation [37], reconstruction of protein-protein interactions [27], ligand binding
site predictions [40], and stability predictions [46].
There are several works that show mutations on functional and structurally
stabilizing sites are strongly related to impaired protein function [5, 43] that
results in diseases. Disease causing P53 structures contains mutations at key
sites that are important for maintaining structural integrity [8,20] and/or contain
mutations in the DNA binding region locally changing the binding affinity and
altering the function [14,28]. Point mutations in the protein stabilizing regions
have also been observed in other diseases including Alzheimer’s, Prion, and
Parkinson’s disease [50]. Mutations at binding sites in proteins are functionally
important as they lead to changes in binding affinity between the protein and
other bio-molecules. The affected binding targets may be ions, other proteins,
ligands, DNA or RNA. A study of somatic mutations in DNA methyltransferase
gene DNMT3A in acute monocytic leukemia found mutations at DNA binding,
cofactor binding, protein-protein interaction sites and Histone H3 peptide binding
sites [47]. These mutations are crucial as they prevent protein complex formation
thereby leading to impaired gene function. Also, rare mutations in DNA-binding
site in POT1 protein have been identified as causal for cutaneous malignant
melanoma as these mutations changed protein folding and binding [41]. Another
study identified somatic mutations in the pre-mRNA binding region in splicing
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factor SF3B1 gene which is known to cause chronic lymphocytic leukemia [39].
These studies highlight the importance of structure-based information in causal
mutation analysis in disease.
Again, it is difficult to obtain similar disease samples, patient’s data alone
may be the only means of determining the causal genes. Considering that the
number of rare variant in rare diseases cases are inherently limited, it is important
to be able to extract information from non-statistical means. Protein structure
provides direct information about the functional importance of loci and does not
rely on statistical means for prioritizing the importance of mutation loci. These
structure-based features need to be extensively tested, especially when several
empirical evidence demonstrate causal mutations at critical structural positions.
Our features are significant in that structure features considers loci information
only, utilizes multiple homolog structures for a given sequence, and considers
the features of structural neighbors.
Contribution
The contributions of the paper are listed as follows:
• Development of loci specific, multi-structural, structural-neighbor consid-
ering features for casual variant prediction.
• Extensive study of the performance of structure-based features in deter-
mining pathogenic effects in point mutations.
• Comparative study of loci specific features using various machine learning
methods and PolyPhen2 [2].
• Demonstrate soundness of generated features for rare variant rare disease
casual mutation predictions.
Materials and methods
Data sets
We generate two data sets, i.e. HumDiv data set, ClinVar dataset, ClinVar
Rare Variant Rare Disease data set to compare and test the performance of
proposed features. Initially, SNV information, including loci, along with the
known functional impact of that variant is extracted from HumDiv database [2]
and ClinVar database [25] separately. HumDiv database contains a total of 13,103
SNVs, which consists of 5,564 pathogenic SNVs that are known to causing human
Mendelian diseases, and 7,539 benign variants that are generated from differences
between human proteins and their closely related mammalian homologs (seqID
>=95%) [2]. Among these, 11,422 have unique variant loci. From the initial
dataset, after filtering out SNV without proper protein structures mapped, 2,473
pathogenic and 2,992 benign (total of 5,465) SNVs remain and are used as
HumDiv dataset. The HumDiv dataset is used mainly for training the model
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and for comparing with a existing SNV classification method, PolyPhen2 [2],
which is a widely used method that includes structural information.
The ClinVar database contains an archive of human variations and phenotypes,
with supporting evidence and is more up-to-date and carefully curated [25]. From
the initial database of 93,946 SNV entries retrieved Jan. 2016, we select 9,286
SNVs with review status 2 through 4 (highest); the review status 2 is ‘SNP
submitted with criteria provided, two or more submitters with no conflicts’;
status 3 is ‘reviewed by an expert panel’; status 4 is ‘practice guideline’. From
the 9,286 SNVs, we selected 6,446 loci labeled as either likely benign or benign
and likely pathogenic or pathogenic without conflicting labels. As the final step,
SNPs without protein structure mapping was removed resulting in a small set
of 438 SNV loci, with 286 pathogenic and 152 benign labels in 101 genes. The
ClinVar dataset is used to test the model learned with HumDiv in the new
dataset.
Rare variants in ClinVar are identified using Ensembl Variant Effect Predictor
tool [30]. This identified 402 rare variants in the ClinVar dataset. An SNV is
considered to be associated with a rare disease if one or more of the diseases
label in ClinVar belong to the list of rare diseases, which is obtained through
Global Genes [15] that lists 6,537 rare diseases, as of August 6, 2017. Among
these rare variants, 117 benign rare variants and 163 pathogenic rare variants
that are identified to be associated with a rare disease are used as ClinVar Rare
Variant Rare Disease dataset.
Features to loci mapping
In order to extract loci specific features, the first step is to retrieve reference
DNA, mRNA, and protein sequences of the corresponding loci. To do this,
we identify genes associated with the variant in the DNA loci represented as
chromosome number and offset value and use biomaRt [13] library to retrieve
reference sequences for DNA (DNA-RefSeq), mRNA (NM-RefSeq) and protein
amino acid sequence (NP-RefSeq) from Ensemble database [3] corresponding to
genome reference HG38 for each dataset. DNA, mRNA, and protein sequences
are then aligned to map the features back the variant loci. Fig 1 shows the steps
involved in the feature generation process utilizing the retrieved sequences and
steps is described in detail in the following feature extraction process description.
Extracting structure-based features
Given a variant locus, the first step of structure-based feature extraction process is
to retrieve protein structure for the locus. To do this, we retrieve a list of protein
structures (PDBIDs) of corresponding NP-RefSeq using protein BLAST [4]
with homology threshold of 60% sequence identity. If structures are found, the
corresponding Protein Data Base (PDB) files are downloaded from RSCB [6]
database. From the PDB structures, PDB sequences are directly extracted
and pair-wise global aligned using a dynamic programming based aligner, i.e.,
FASTA align [35]), to the protein reference sequence (NP-RefSeq). Corresponding
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Figure 1: Loci specific feature extraction pipeline.
reference mRNA sequence (NM-RefSeq) of the NP-RefSeq is then aligned to
reference DNA (NC-RefSeq) using Splign [22], which allows alignment even in
the presence of splice sites. Finally, the structure-based features are generated
and mapped to the variant locus.
Structural neighborhood
Features generated from structural neighboring are one of the novel contribution
of our proposed method. Before details on the description of structure-based
feature extraction process, we first define the structural neighborhood. Structure-
based features are defined for the amino acid at the variant site, and a cumulative
value representing the amino acids in the neighborhood of the query amino acid.
The neighborhood is defined as the set of amino acid residues that lie within
a specified radius of the physical structure of the protein centered around the
query variant site. Based on the relative Cartesian coordinates of the amino
acids in the PDB files, we consider the neighborhood as all the residues located
within the Euclidean distance of 9 Angstroms (A˚), as shown in Fig 2. We
take summaries of the feature values calculated for neighboring amino acids as
the neighborhood features. Also, the number of residues in the neighborhood
(nNum) is also included as one of the neighborhood features. Since neighborhood
information is extracted from a structure, all the neighborhood features are we
considered to be structure features.
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Figure 2: Structural neighbourhood Yellow sphere depicts a radius of 9A˚ and
all amino acids residues found within this region are considered as neighbours of
the query site. PDBID:1IJN centered at 116.A
Structure-based features
Next, we provide details on the extraction of eleven structure-based features that
combine information from multiple homologous structures. Again, the eleven
features depend on the location of the variant and not on the actual change
and are considered prior knowledge. Also, unlike many existing methods, we
emphasize the importance of obtaining information from multiple structures. A
PDB structure is only a static snapshot of the true protein and the functional
information such as binding event may exist in one structure while not on
another depending on the experimental settings, thus examining all homologous
structures is important.
The first structure-based feature is the binding site information (Binding).
The binding feature is generated by finding ligands, ions, and other biomolecules
that are within a threshold distance to the protein structure. For small molecules,
i.e., ion binding site and protein-ligand binding site, we used a threshold of 4.5A˚.
For larger binding targets, i.e., DNA, RNA, and protein-protein binding sites, we
used a threshold of 8A˚. If a target molecule is observed within the threshold, then
the corresponding binding site bin from the five categories is set to 1. Binding
information from multiple structures is integrated using binary OR operation
to represent all cases of possible binding sites at the query site among multiple
structures. Based on the five binding target information extracted from the
structure, we add the values such that the resultant feature represents the number
of different binding types found at the query site. Binding information for the
neighbourhood (nBinding) is calculated by binary OR the binding information
from structural neighbours.
The second type of structure-based feature is hydrophobicity (KDmean).
KDmean is the mean value of Kyle Doolittle (KD) hydrophobicity [24] values
of amino acids observed at the query location from multiple aligned structures.
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The mean KD hydrophobicity value of the structural neighborhood is also used
(nKD).
The third type of features is the solvent accessibility. Solvent accessibility
is the surface area which is reachable by a solvent and is measured by squared
Angstroms. DSSP [21, 44] is used to calculate the initial solvent accessibility.
After which the accessibility value is divided by the maximum exposure value
possible for the amino acid triplets centered around the mutation point to obtain
Residual Solvent Accessibility (RSA) value. The maximum RSA value (RSAmax )
is chosen as a feature to represent information from multiple structures. Mean
of the maximum RSA values of amino acids in the neighborhood (nRSA) is also
used.
Fourth feature type is B factor. B factor is a temperature dependent pa-
rameter which describes the displacement of atomic positions from their mean
position that indirectly accounts for the flexibility of the locus. This feature
for a given amino acid is obtained directly from the PDB files. We use the
standard deviation of B-factor (Bstddev) values to represent the variability of
this parameter in multiple structures as a feature and the mean B-factor value
of amino acids in the neighborhood (nB)as the neighbor feature.
Fifth feature type is based on sequence conservation. The sequence conserva-
tion of the locus is considered as a sequence-based property, and the method
of calculating this value is described in the next section. However, since the
neighborhood is a structurally defined concept, mean of sequence conservation of
amino acids in the neighborhood (nSC ) is included as a structure-based feature.
The last structure-based feature type comes from Ramachandran plot. The
Ramachandran plot depicts the phi-psi angles of amino acids in a given protein
structure. The Ramachandran plot is partitioned into regions where a secondary
structure is more likely to be found. To generate related feature we use PolyPhen2
web server to get MapReg feature for a locus. Based on the MapReg feature
generated, we represent our feature as a binary value (Mapreg) describing whether
the mutation site belongs to core regions(represented by symbols A, L, B, P), or
not.
Extracting sequence-based features
There are five sequence-based features tested that are specific to the prior
loci-based information about the variant and are not dependent on the change.
The first is the sequence conservation (SeqCons). The sequence conservation
implies the how conserved the locus is throughout the evolution process. The
assumption being that the locus that is unchanged over the evolution process must
be functionally important. The sequence conservation is indirectly computed by
calculating the variation of amino acids in loci. That is, after multiple sequences
aligning via ClustalW [16,26] the query sequence with the homologous sequence
extracted from MetaPhOrs API [38], a variation of an amino acid at a mutation
point is calculated and conservation score is computed using the Jensen-Shannon
divergence. Four additional features are adapted from sequence-based features
of PolyPhen2 from DNA and protein levels. At the DNA level, the position
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variant locus within the codon (CodPos) and the distance of the variant locus
from the closest intron/exon junction (MinDJxn) are identified and included as
a sequence-based features. At the protein level, Position-Specific Independent
Counts (PSIC ) score [42] of the wild type amino acid residue and the number of
amino acids observed at variant locus (Nobs) during multiple sequence alignment
of homologous sequences are used. The list of features is summarized in Tab 1.
Table 1: List of structure- and sequence-based features. The rank represents
the importance of individual features obtained by 5-fold cross validation on the
HumDiv training data using MLP for attribute evaluation.
Name Description Rank
Structure based features
nNum number of amino acids whin structural neighborhood 2
RSAmax maximum residual solvent accessibility value 3
nRSA mean residual solvent accessibility of structural
neighbors
4
nB mean B factor of structural neighbors 5
nBinding whether neighbors have a binding site or not 7
nKD mean KD hydrophobicity of structural neighbors 9
Bstddev standard deviation of B factors 10
Mapreg whether variant locus is within core region of phi-psi
Ramachandran map (PolyPhen)
11
nSC mean sequence conservation of structural neighbors 12
KDmean mean KD hydrophobicity value 13
Binding whether site is binding or not 14
Sequence based features
PSIC PSIC score of wild type amino acid (PolyPhen) 1
SeqCons sequence conservation 6
Nobs number of amino acid observed at the substitution
position in the multiple alignment (PolyPhen)
8
CodPos position of variant locus within a codon (PolyPhen) 15
MinDJxn distance of variant locus from closest exon/ intron
junction (PolyPhen)
16
Results
Classification performance
Classification accuracies of seven machine learning algorithms are measured to
validate the effectiveness of the proposed loci-based features. The goal of the
learning task is to classify a variant site as pathogenic or benign based on the
features defined at the variant locus. For HumDiv dataset, the data is randomly
split such that 80% is used for training and validation and 20% is used for testing.
9
We additionally test the model on ClinVar dataset, i.e. small but newer and
cleaner dataset, using the learned model. The 20% of training data is used as a
validation set to tune hyperparameter of each machine learning algorithms. Seven
machine learning algorithms used are naive Bayes, support vector machine (SVM;
LibSVM implementation [10]), logistic regression, multi-layer perceptron (MLP),
k-nearest neighbors(KNN), decision table, and random forest. All experiments
are performed using Weka [18, 45] and Weka’s unsupervised attribute filter is
used for replacing missing values in the test set based on means and modes of
training data.
To validate the performance of the features, we use weighted F-score calculated
by Weka. The precision-recall based scores are known to be a measurement
of choice when there is a class imbalance as in the case of our test sets. The
weighted F score is a weighted average of the precision and recall that account
for both the correctly predicted positives as well as incorrectly predicted positive
and negatives. The weighted F score reaches its best value at 1 and worst at 0.
Performance variation of learning methods
First, we test the models learned on HumDiv test datasets consisting of 1094
SNVs. The summary of the weighted F score values are shown in Tab 2. We
can see that random forest provide the best scores going up as high as weighted
F score of 0.85.
Table 2: Classification performance on HumDiv dataset. Summary of
weighted F scores for each algorithm using sequence-based features, structure
features and the combination of sequence and structure features (combined).
Algorithm Sequence only Structure only Combined
Naive Bayes 0.82 0.71 0.80
SVM 0.79 0.69 0.81
Logistic regression 0.79 0.69 0.80
MLP 0.78 0.71 0.82
KNN 0.83 0.72 0.80
Decision table 0.81 0.74 0.82
Random forest 0.83 0.76 0.85
Then we test if the model can be transferred to test the ClinVar dataset
consisting of 438 loci with 286 pathogenic and 152 benign labels in 101 genes.
The Tab 3 summaries the results. Although MLP does have the highest F score
in the ClinVar test case, there is no clear winner in terms of learning methods.
Also, compared to the result of HumDiv test case, F score decreased overall with
highest weighted F score being 0.75. This was expected since ClinVar labeling
and HumDiv labeling criterion and the selection of benign cases are slightly
different. With a consistent dataset, we expect that the F score will increase.
With the difference in the distribution of training set and testing set in mind,
we will focus our analysis using ClinVar dataset which consists of labels that are
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better curated. Also, the choice of learning method was unimportant and we
were able to get stable results using most of the learning methods.
Table 3: Classification performance on ClinVar dataset. Summary of
weighted F scores for each algorithm using sequence-based features (sequence),
structure-based features (structure) and the combination of sequence- and
structure-based features (combined).
Algorithm Sequence Structure Combined
Naive Bayes 0.69 0.69 0.72
SVM 0.70 0.66 0.72
Logistic regression 0.70 0.65 0.72
MLP 0.70 0.68 0.75
KNN 0.69 0.70 0.71
Decision table 0.68 0.64 0.70
Random forest 0.69 0.69 0.72
Performance comparison between sequence- and structure-based fea-
tures
Tested on HumDiv dataset, the sequence-based features, with a maximum value
of 0.83, performed better than structure-based features, with a maximum value
of 0.76. Interestingly the difference was minor for the ClinVar dataset with
maximum weighted F score of 0.70 for sequence-based and 0.69 for structure-
based features. The weighted F score for combined features performed best for
the majority of the tested learning methods in HumDiv test dataset and all
learning methods in ClinVar dataset. This shows that, although the performance
of structure-based features is similar or even lower, structure-based features are
contributing in terms of predicting the important of the loci in disease. We
again emphasize that the current features used are prior information about the
importance of a locus in the disease process.
In addition to weighted F score comparison, we examined the importance
of individual features on the training data using MLP. The feature ranks are
shown in the third column of Tab 1. Four structure-based features and one
sequence-based features are ranked within top 5 and three out of four structure-
based features where neighborhood features. Overall, the results tell us that
structure-based features are informative and that structure-based features and
sequence-based features are complementary.
Importance of neighborhood information
We next tested the contribution of structural neighborhood features in improving
the classification performance. To do this, the performance of structure-based
features with and without the neighborhood information was measured as shown
in Tab ??. It can be seen that neighborhood information improves the weighted
F score for learning algorithms tested on HumDiv test and ClinVar datasets.
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Table 4: Classification performance of structure-based features with and without
neighbourhood information. The values represent the weighted F scores.
Dataset Algorithm Without Neighbourhood With Neighbourhood
HumDiv MLP 0.70 0.71
HumDiv Random Forest 0.73 0.76
ClinVar MLP 0.64 0.68
ClinVar Random Forest 0.66 0.69
Performance comparison
We compare our selection of features that consist only of variant loci based, i.e.
prior information, with the PolyPhen2 that considers both loci based features and
nucleotide change based features, i.e, requiring information about the what the
nucleotide change. The ClinVar dataset is used since the PolyPhen2’s models are
trained on HumDiv dataset. We compared the predictions of our features using
MLP and Random Forest with PolyPhen2 predictions that are obtained from
PolyPhen2 web server (URL: http://genetics.bwh.harvard.edu/pph2/). Test
results are summarized in Tab 5.
Interestingly, our loci-based features performed comparable and even slightly
better (MLP weighted F score of 0.75 compared to 0.74) than the PolyPhen2
predictions that use nucleotide change based information in addition to loci-based
information. To test how much the nucleotide change information contributes,
we also tested PolyPhen2’s six nucleotide change (DNA change) based features,
as listed in the Supplementary text: S1 Table, in addition to our loci-based
features. With the added features the weighted F scores improved as shown
in third column of Tab 5. We emphasize again that the purpose of the work
is to test how much a non-statistics based prior information contributes in the
determination of the pathogenic effect of variant such that it can be used toward
rare variant rare disease cases. With the purpose in mind, interestingly variant
loci seem to contribute largely in determining the pathogenic effects.
Table 5: Comparison of algorithm performance with PolyPhen2 predictions. The
values represent the weighted F scores for ClinVar dataset.
Our proposed features via MLP PolyPhen2
Algorithm Loci based DNA change
0.74MLP 0.75 0.79
Random Forest 0.72 0.78
Examining rare variants in rare disease cases
To analyze the performance of the model for the rare variant in rare disease
cases which is the goal of the work, we identify rare variants (MAF<0.01) in the
dataset and check if they were related to a rare disease. The ClinVar dataset
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contains 163 pathogenic rare variants and 117 benign rare variants as described
in the dataset section.
The Tab 6 summarizes weighted F score for sequence-based (sequence),
structure-based (structure), sequence- and structure-based features combined
(combined), and nucleotide change included features (DNA change). Comparing
the number of correctly predicted benign cases (52 vs 79) and pathogenic cases
(137 vs 110) we can see that sequence-based features were able to predict more
pathogenic cases and structure-based features were able to predict benign cases
better. Combined features increased the number of correctly predicted and
adding DNA change information improved the result slightly more by increasing
the number of correctly predicted pathogenic cases.
Table 6: Rare variant and rare disease SNVs predictions, based on prior informa-
tion. The values represent the number of correctly classified (out of 117 benign,
163 pathogenic) based on MLP prediction model.
Our proposed features via MLP
PolyPhen2
Sequence Structure Combined DNA change
Benign (TN) 52 79 68 62 49
Pathogenic (TP) 137 110 137 149 150
TP+TN 189 189 205 211 199
weighted F score 0.66 0.68 0.73 0.74 0.69
Structural examination of rare variant in rare disease
To understand how the structure-based features perform in more detail, we take
a detailed look at cases where structure-based features performed well while all
others were not successful.
Figure 3: Two pathogenic rare variants ACADM gene The SNV loci of
Chr1:75761161 and Chr1:75732724 corresponding to ACADM gene mapped to
PDBID:2A1T.A positions 304 in A (green) and 42 in B (blue), respectively. An
SVN locus depicted in spheres and neighborhoods in transparent spheres. The
two variant loci are known to be pathogenic in Medium-chain acyl-coenzyme A
dehydrogenase deficiency.
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First, we examine two rare variants in chromosome 1 positions 75761161 and
75732724. The two loci are associated with Medium-chain acyl-coenzyme A
dehydrogenase deficiency (MCADD) which is a metabolic disorder that prevents
the body from converting certain fats to energy and variants in ACADM gene is
known to cause this MCADD in an autosomal recessive manner. The SNV locus
Chr1:75761161 depicted in Fig 3A shows that the locus is a domain binding
site. The structure-based features also shows that the neighborhood is mostly
hydropathic (nKD=1.14) and is surrounded by many residues (nNum=17). Also,
SNV locus Chr1:75732724 depicted in Fig 3B shows that the locus is a surface
region and a not binding site, however, since the neighborhood is hydropathic
and stable (relatively low nB of 38), the locus may be part of a transient binding
site. For both loci, the sequence base features predict this SNV locus as benign
with no strong features to indicate pathogenic effects.
Figure 4: Three benign rare variants in the flexible solvent acces-
sible areas A. Shows SNV locus Chr13:32379392 of BRCA2 gene mapped
to PDBID:1MIU.A position 2865. B. Shows SNV locus Chr13:32338940
(NM000059.3 : c.8567A > CGRCh38) of BRCA2 gene mapped to
PDBID:1N0W.B position 1529. C. Shows SNV locus Chr21:34370500 of KCNE2
gene mapped to PDBID:2M0Q.A position 8. Variant loci are depicted in spheres
and neighborhoods in transparent spheres. All three SNV loci are known to
benign.
We next look at three SNV loci that are located at flexible solvent accessible
areas. Fig 4A and 4B show two protein structures that are associated with
BRCA2 gene. The SNVs at the two loci are known to be benign. Looking
at SNV locus Chr13:32379392 in Fig 4A, we can see that it is part of tower
region of the protein structure (PDBID:1N0W) with high exposure to solvent
(nRSA=0.46) with low hydrophobicity value (nKD=-1.03) which says that it
is not directly binding region although the three helical bundle at the tip of
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the tower is known to bind to DNA [48]. SNV locus in Fig 4B is part of BRC
repeat 4 (BRC4) that is bound to RAD51. BRC repeats are known to be well
conserved and are the primary sites through which BRCA2 binds to RAD51
that has a critical role in DNA recombination [36]. In contrary to the suggestion
of the structure provider of PDBID:1N0W that the variant locus should be
pathogenic [36], ClinVar’s expert panel find the variant benign. We find that this
region, although it is a binding site, is beta turn region which is more flexible
solvent accessible region. Fig 4C depicts SNV locus Chr21:34370500 of KCNE2
gene mapped to PDBID:2M0Q.A at position 8. 2M0Q is a transmembrane helix
structure and the SNV locus is positioned at the tip of a more flexible area of the
structure. With the three cases, we find that variant at loci of flexible solvent
accessible areas tends to be benign.
Figure 5: A benign rare variant in FANCI gene The SNV locus of
Chr15:89285210 corresponding to FANCI gene map to PDBID:3S4W.A po-
sitions 604. Variant loci is depicted in spheres and neighborhoods in transparent
spheres. The two variant loci are known to be benign in Fanconi anemia.
Final we look a benign SNV locus Chr15:89285210 corresponding to FANCI
gene. FANCI gene is known to be associated with Fanconi anemia which is
a rare disease in the category of bone marrow failure syndromes. Fanconi
anemia is often associated with a progressive deficiency of all bone marrow
production of blood cells, red blood cells, white blood cells, and platelets. Fig 5
depicts PDBID:3S4W which FANCI structure (blue) is bound to FANCD2 (gray)
structure. The two complex is known to bind to DNA structure at the center of
the curved region. The SNV locus is completely buried but has relatively flexible
with high B-score of 70. The region is not associated with protein-protein binding
nor protein-DNA binding. Structure-based feature predicts this as benign while
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as sequence-based features and HumDiv predicts it pathogenic.
Discussions and Conclusions
Determination of whether a variant or group of variants have pathogenic effects
involves various factors. To understand the effect of variants better we separate
out the features that can be predetermined based on the locus of the variant and
the features that are dependent on the changed in the DNA sequence. The loci-
based information can be considered as prior information since the importance
of loci can be pre-calculated. Also, structure-based loci features do not depend
on statistical means which makes it attractive for rare variant rare disease cases.
Our results show that sequence-based features perform slightly better than
structure-based features in classify pathogenic variants. However, structure-
based features provide a complementary information and when combined with
sequence-based features, it improves the F score up to 0.85 in the HumDiv
dataset. In theory, the sequence contains all necessary information, however, we
still don’t know how and structure-based information can fill in this knowledge
gap.
In terms of structure-based features, there are two novel contributions that
seem to improve the performance: we use multiple homologous structures and we
used features from the structural neighborhood. The newly introduce structure-
based features in combination with sequence-based features of loci information
only performs comparably to the PolyPhen2 that utilized loci information as
well as the DNA change information. Also, empirical structure-based features
of rare variant in rare disease cases show that structure-based features play an
important role in correctly classifying benign verse pathogenic cases.
Many previous causal variant prediction methods consider structure-based
features as minor factors even though there are several works that say structure-
based features are important. It is true that structures are more difficult to
work with compared to sequences and extracting structure-based features from
given structures are not trivial. Even after successfully extracting features from
structures, correctly mapping it back to the original DNA sequence is difficult
due to several difficulties, including differential splicing and miss match in a start
position of reference protein sequence to the PDB protein sequence is challenging.
Also, structure-based features have relatively small coverage and data available
compared to sequential data. Even with this challenges, our work has shown
that loci of the variant event plays a key role in determining the pathogenic
effect and showed that the structure-based features can in cases classify better as
shown in rare variant rare disease cases. In the future, we would like to include
more structure-based features utilizing computational methods such as binding
site predictions, and stability predictions and also increase coverage by including
structure prediction methods.
16
Supporting information
S1 Table. Nucleotide change based features. To identify the information
gain, we also tested six variant-based features in addition to loci information
for evaluation. Each of features are obtained from PolyPhen2 server (URL:
http://genetics.bwh.harvard.edu/pph2/dokuwiki/appendix a ).
Feature Description
Score2 the PSIC score for mutant amino acid
dScore represents the difference PSIC and Score2
Transv represents if the substitution is a transversion
CpG values represent change in CpG content due to substitution
IdPmax represents mutant amino acid’s maximum congruency in multiple
sequence alignment
IdQmin represents the sequence identity to closest homologue deviating
from wild type amino acid
S2 HumDiv training set. List of HumDiv training set features and meta
data.
S3 HumDiv test set. List of HumDiv test set features and meta data.
S4 ClinVar data set. List of ClinVar test set features and meta data.
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